News | News By Subject | News by Disease News By Date | Search News

Renal Cell Carcinoma News Articles

Get Our FREE
Industry eNewsletter
email:    
Top Breaking News
Cerulean (CERU) Shares Decimated as Renal Cell Carcinoma Drug Comes Up Short in Mid-Stage Study     8/18/2016
Pfizer (PFE) Stock Climbs With Positive Renal Cancer Phase III Data     7/8/2016
Mologen (MOLGF.PK) Restructures, Pushes Immunology Program, Shelves Renal Cancer Vaccine     6/9/2016
Exelixis (EXEL)' Cabozantinib Met Primary Endpoint in Phase II Renal Cell Carcinoma Study     5/23/2016
Exelixis (EXEL)'s Cabozantinib Shines in Late Stage Study for Patients with Advanced RCC     1/6/2016
AVEO Oncology (AVEO), EUSA Pharma Form $396.5 Million Exclusive Licensing Agreement for Tivozanib in Europe     12/21/2015
Bristol-Myers Squibb (BMY) Grabs Breakthrough Tag for Opdivo     9/16/2015
Revitalized Exelixis (EXEL) Grabs Breakthrough Tag for Cabozantinib     8/25/2015
Bristol-Myers Squibb (BMY)'s Opdivo Phase III Study Stopped Early on More Good Cancer Therapy News     7/21/2015
Embattled Exelixis (EXEL) Nabs Much-Needed Victory for Phase III Renal Cell Carcinoma Study     7/21/2015
Analyst: Current Crop of Biotech IPOs a Mixed Bag of Low Market Caps, Little Data     12/3/2014
Best Value In Biotech? Actavis (ACT), Says UBS     11/17/2014
Bionomics Limited (BNO.AX) Sinks As Renal Cancer Drug Fails Key Phase 2 Test     3/19/2014
FDA Committee Turns Down AVEO Oncology (Formerly known as AVEO Pharmaceuticals, Inc.) (AVEO)/Astellas Pharma Inc. (YPH.BE)'s Cancer Drug     5/6/2013
Pfizer Inc. (PFE) Kidney Cancer Drug Fails as Initial Treatment     10/18/2012

News from Around the Web

Press Releases
Xynomic Pharma And UCSF Entered Strategic Partnership In Conducting A Phase II/III Trial Of Abexinostat Against Renal Cell Carcinoma     5/22/2017
AVEO Oncology (AVEO) Announces Completion Of A CHMP Oral Explanation For Tivozanib As A Treatment Of First-Line Renal Cell Carcinoma     5/19/2017
Argos (ARGS) Provides Update On Its ADAPT Trial Following Meeting With FDA     5/10/2017
Exelixis (EXEL) And Bristol-Myers Squibb (BMY) Enter Clinical Collaboration for Late-Stage Combination Trial in First-Line Renal Cell Carcinoma     2/27/2017
Committee Recommends Discontinuation of Argos (ARGS)' Phase III Renal Cell Carcinoma Study     2/22/2017
Nektar Therapeutics (NKTR) Release: Clinical Data From Phase I Dose-Escalation Study Of Single-Agent NKTR-214 In Patients With Renal Cell Carcinoma Presented At The ASCO 2017 Genitourinary Cancers Symposium     2/20/2017
Phase II Study Supports Potential For Genentech (RHHBY)’s Tecentriq (Atezolizumab) Plus Avastin (Bevacizumab) For People With Locally Advanced Or Metastatic Renal Cell Carcinoma     2/20/2017
X4 Pharma Release: Company Announces Initiation Of Clinical Study Of X4P-001 In Combination With Opdivo For Patients With Advanced Clear Cell Renal Cell Carcinoma     1/26/2017
TRACON Pharma (TCON) Presents Final Updated Phase Ib Results For TRC105 In Combination With Inlyta In Renal Cell Carcinoma At The ESMO 2016 Congress     10/10/2016
Eisai Inc. (ESALF.PK) Release: Now Enrolling: Global Phase 3 Clinical Trial To Evaluate Potential First-Line Use Of Lenvatinib In Combination With Pembrolizumab Or Everolimus For Patients With Advanced Renal Cell Carcinoma     9/29/2016
First Patient Enrolled In Toca 6, Tocagen's Trial For Metastatic Cancers Evaluating Intravenously Delivered Toca 511 Virus     9/22/2016
Eisai Company (ESALY.PK) Receives License For New Indication For Anticancer Agent Kisplyx (Lenvatinib Mesylate) For Treatment Of Advanced Renal Cell Carcinoma     9/15/2016
European Commission (EC) Approves Ipsen (IPN.PA)’s Cabometyx (Cabozantinib) Tablets For The Treatment Of Advanced Renal Cell Carcinoma (RCC) In Adults Following Prior Vascular Endothelial Growth Factor (VEGF)-Targeted Therapy     9/14/2016
Cerulean (CERU) Announces Results From Phase 2 Clinical Trial Of CRLX101 And Avastin Combination In Relapsed Renal Cell Carcinoma     8/18/2016
AVEO Oncology (AVEO) Initiates The Evaluation Of Tivozanib In Combination With Bristol-Myers Squibb (BMY)’s Opdivo (Nivolumab) In Advanced Renal Cell Carcinoma     8/15/2016

//-->